Stock Events

Stock Events

Adicet Bio 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q4 2025
Next
-9.38
-7.1
-4.81
-2.53
Expected EPS
-9.3808
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1IJ.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Fate Therapeutics
FATE
Mkt Cap141.84M
Fate Therapeutics is focused on the development of programmed cellular immunotherapies for cancer and immune disorders, similar to Adicet Bio's focus on cell therapies for cancer, making them direct competitors in the cell therapy space.
Allogene Therapeutics
ALLO
Mkt Cap604.57M
Allogene Therapeutics operates in the field of allogeneic CAR T cell therapies, directly competing with Adicet Bio's allogeneic cell therapy approach for treating cancer.
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
CRISPR Therapeutics is engaged in gene editing and CAR-T therapy developments, competing in the innovative therapy space including cancer treatments, overlapping with Adicet Bio's focus areas.
Novartis
NVS
Mkt Cap297.32B
Novartis is a large pharmaceutical company with a strong presence in the cell therapy market, including Kymriah, a CAR-T therapy for cancer, making it a competitor to Adicet Bio.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences, through its acquisition of Kite Pharma, has become a leader in CAR-T therapy for cancer, directly competing with Adicet Bio's cell therapy approaches.
Precigen
PGEN
Mkt Cap1.39B
Precigen is a biotechnology company that develops gene and cell therapies, including CAR-T therapies for cancer, making it a competitor in the same field as Adicet Bio.
Sangamo Therapeutics
SGMO
Mkt Cap124.32M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, gene editing, and cell therapy for cancer and other diseases, competing in the same innovative therapy areas as Adicet Bio.

About

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.
Show more...
CEO
Mr. Chen Schor BA, CPA, M.B.A.
Employees
102
Country
United Kingdom
ISIN
US0070022076

Listings

MU
DE
1IJ.MU
STU
DE
1IJ.STU
LSE
GB
0HX7.LSE
XNAS
US
ACET

0 Comments

Share your thoughts

FAQ

What is Adicet Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Adicet Bio stocks are traded under the ticker 1IJ.MU.
When is the next Adicet Bio earnings date?▼
Adicet Bio is going to release the next earnings report on May 12, 2026.
What were Adicet Bio earnings last quarter?▼
1IJ.MU earnings for the last quarter are -2.55 EUR per share, whereas the estimation was -2.53 EUR resulting in a -1.03% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Adicet Bio have?▼
As of April 12, 2026, the company has 102 employees.
In which sector is Adicet Bio located?▼
Adicet Bio operates in the Other sector.
When did Adicet Bio complete a stock split?▼
Adicet Bio has not had any recent stock splits.
Where is Adicet Bio headquartered?▼
Adicet Bio is headquartered in Boston, United Kingdom.